WO2001000196A3 - Mirtazapine for weight gain in wasting diseases - Google Patents

Mirtazapine for weight gain in wasting diseases Download PDF

Info

Publication number
WO2001000196A3
WO2001000196A3 PCT/US2000/017432 US0017432W WO0100196A3 WO 2001000196 A3 WO2001000196 A3 WO 2001000196A3 US 0017432 W US0017432 W US 0017432W WO 0100196 A3 WO0100196 A3 WO 0100196A3
Authority
WO
WIPO (PCT)
Prior art keywords
mirtazapine
wasting diseases
cancer
wasting
weight gain
Prior art date
Application number
PCT/US2000/017432
Other languages
French (fr)
Other versions
WO2001000196A2 (en
Inventor
Michael A Weitzner
David V Sheehan
Original Assignee
Univ South Florida
Michael A Weitzner
David V Sheehan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida, Michael A Weitzner, David V Sheehan filed Critical Univ South Florida
Priority to AU57649/00A priority Critical patent/AU5764900A/en
Publication of WO2001000196A2 publication Critical patent/WO2001000196A2/en
Publication of WO2001000196A3 publication Critical patent/WO2001000196A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method for ameliorating the loss of lean body mass that accompanies wasting diseases such as cancer cachexia and anorexia, AIDS, anorexia nervosa, and wasting conditions arising from other medical treatments such as cancer chemotherapy. Mirtazapine, 1,2,3,4,10,14b-hexahydro-2-methyl-pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine (Org 3770), is administered as a pharmaceutically acceptable salt in an efficacious dosage, preferably orally, and preferably at a dosage of 7.5 to 45 mg per day. Either (R), (S), or a racemic mixture of mirtazapine enantiomers may be used. The invention provides improved quality of life for patients suffering from wasting diseases, and improves the ability of cancer patients to tolerate chemotherapy.
PCT/US2000/017432 1999-06-25 2000-06-26 Mirtazapine for weight gain in wasting diseases WO2001000196A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU57649/00A AU5764900A (en) 1999-06-25 2000-06-26 Mirtazapine for weight gain in wasting diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14075399P 1999-06-25 1999-06-25
US60/140,753 1999-06-25

Publications (2)

Publication Number Publication Date
WO2001000196A2 WO2001000196A2 (en) 2001-01-04
WO2001000196A3 true WO2001000196A3 (en) 2002-01-10

Family

ID=22492658

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/017432 WO2001000196A2 (en) 1999-06-25 2000-06-26 Mirtazapine for weight gain in wasting diseases

Country Status (2)

Country Link
AU (1) AU5764900A (en)
WO (1) WO2001000196A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
US20140271727A1 (en) * 2013-03-18 2014-09-18 National Yang-Ming University Method of using an antidepressant for increasing immunity of a subject and treating cancer
FR3015289B1 (en) * 2013-12-20 2017-01-13 Virbac MIRTAZAPINE INJECTABLE
CA2961410C (en) 2014-09-16 2023-07-11 India Globalization Capital, Inc. Cannabinoid composition and method for treating pain
WO2016118391A1 (en) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
WO2017027651A1 (en) 2015-08-12 2017-02-16 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
CA3027862A1 (en) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders
CA3054589A1 (en) * 2017-02-28 2018-09-07 India Globalization Capital, Inc. Method and composition for treating eating disorders
CN113602530A (en) * 2021-07-11 2021-11-05 西北工业大学 Novel single-degree-of-freedom foldable columnar structure

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0813873A1 (en) * 1996-06-19 1997-12-29 Akzo Nobel N.V. Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0813873A1 (en) * 1996-06-19 1997-12-29 Akzo Nobel N.V. Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ABED R.T. ET AL: "Mirtazepine causing hyperphagia [6].", BRITISH JOURNAL OF PSYCHIATRY, (1999) 174/FEB. (181)., XP001030473 *
FAWCETT J ET AL: "Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression.", JOURNAL OF AFFECTIVE DISORDERS, (1998 DEC) 51 (3) 267-85. REF: 79, XP001031559 *
MONTGOMERY S A ET AL: "Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study.", INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, (1998 MAR) 13 (2) 63-73., XP001030478 *
PIRL W.F. ET AL: "Diagnosis and treatment of depression in cancer patients.", ONCOLOGY, (1999) 13/9 (1293-1306)., XP001030472 *
ROTH, A.J. ET AL.: "Treatment of Depression in Cancer Patients", PRIMARY CARE AND CANCER, vol. 14, no. 1, 1994, pages 23 - 29, XP001030635 *
SITSEN, J.M.A. ET AL.: "Mirtazapine. Clinical profile", CNS DRUGS, vol. 4, no. 1, 1995, pages 39 - 48, XP001031860 *

Also Published As

Publication number Publication date
WO2001000196A2 (en) 2001-01-04
AU5764900A (en) 2001-01-31

Similar Documents

Publication Publication Date Title
US6656945B2 (en) 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction
CA2226784C (en) Use of cgmp-phosphodiesterase inhibitors to treat impotence
CA2176604A1 (en) Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin
RU2003135482A (en) HEROPROTECTOR BASED ON HYDROGEN PYRIDO (4,3-B) INDOLES (OPTIONS), PHARMACOLOGICAL PRODUCT ON ITS BASIS AND METHOD OF ITS APPLICATION
NO20044974L (en) Imidazo [1,2-a] pyrazin-8-ylamines, Methods of Preparation and Use thereof
CA2263561A1 (en) Thienopyrimidines
AU5895496A (en) Phenyldihydrobenzofurans
CA2306393A1 (en) Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization
CA2314993A1 (en) Combination effective for the treatment of impotence
MY118156A (en) Oral compositions of levosimendan.
CA2307101A1 (en) Pharmaceutical articles of manufacture comprising selective phosphodiesterase inhibitors for the treatment of sexual dysfunction
WO2001000196A3 (en) Mirtazapine for weight gain in wasting diseases
WO1999052514A3 (en) Pharmaceutical composition and combination preparation for immunosuppressive therapy
AU5764496A (en) Cyclohexyl dihydrobenzofuranes
DE50211929D1 (en) Pyrimidinderivate
CA2379752A1 (en) Use of agonists of gabab receptors and pharmaceutically acceptable derivates thereof, in the therapy of maintaining nicotine abstinence-dependent patients
WO2004096118B1 (en) Composition for improving cognition and memory
CA2306748A1 (en) Treatment of fibromyalgia and related disorders
WO2001030331A3 (en) Therapeutic compositions including protein kinase c inhibitors
JP2003522768A5 (en)
CA2272732A1 (en) Hemorrhoidal treatment composition
EP1136072A1 (en) Preparations for intraurethral administration
CA2188297A1 (en) Lactone stable formulation of camptothecin or 7-ethyl camptothecin
EP0785787A1 (en) Use of 1,5-benzodiazepine derivatives for the control of gastric emptying in patients with non-insulin dependent diabetes mellitus
CA2336194A1 (en) 1-(aminoalkyl)-3-quinoxaline-2-one derivatives for the preparation of compounds having an antioxidant action

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP